Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries
- 28 February 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (6), 846-848
- https://doi.org/10.1136/annrheumdis-2019-216702
Abstract
No abstract availableFunding Information
- Pfizer
This publication has 5 references indexed in Scilit:
- To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registryAnnals Of The Rheumatic Diseases, 2018
- Consensus-based recommendations for the use of biosimilars to treat rheumatological diseasesAnnals Of The Rheumatic Diseases, 2017
- Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohortsBritish Journal of Dermatology, 2016
- Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo: Table 1Annals Of The Rheumatic Diseases, 2016
- The changing landscape of biosimilars in rheumatologyAnnals Of The Rheumatic Diseases, 2016